10-Q: Prestige Consumer Healthcare Reports Slight Revenue Dip in Q2 2025, Maintains Profitability

Prestige Consumer Healthcare experienced a minor decrease in revenue for the second quarter of fiscal year 2025, while maintaining profitability.

Summary

• Prestige Consumer Healthcare's total revenue for the quarter ended September 30, 2024, was $283.8 million, a slight decrease of 0.9% compared to the same period in 2023.
• The North American OTC Healthcare segment saw a revenue decrease of 1.9%, while the International OTC Healthcare segment experienced a 5.0% increase.
• Gross profit decreased by 1.6% to $157.4 million, with a gross profit margin of 55.5%.
• Net income for the quarter was $54.4 million, compared to $53.6 million in the prior year.
• Basic earnings per share were $1.10, and diluted earnings per share were $1.09.
• For the six months ended September 30, 2024, total revenue was $550.9 million, a decrease of 2.6% compared to the same period in 2023.
• Net income for the six-month period was $103.4 million, compared to $106.8 million in the prior year.
• The company repurchased shares of its common stock for $11.8 million during the quarter and $37.8 million during the six month period.
• The company had $51.5 million in cash and cash equivalents as of September 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company remains profitable, the revenue decline, supply chain issues, and reliance on third-party manufacturers raise concerns. The company's share repurchase program and reduced borrowing costs are positive signs, but the overall outlook is mixed.

Positives

• Net income increased slightly for the quarter to $54.4 million.
• The International OTC Healthcare segment showed revenue growth of 5.0%.
• The company's average cost of borrowing decreased.
• The company repurchased shares of its common stock, indicating confidence in its value.
• Cash and cash equivalents increased to $51.5 million.

Negatives

• Total revenue decreased by 0.9% for the quarter and 2.6% for the six month period.
• The North American OTC Healthcare segment experienced a revenue decline of 1.9% for the quarter and 3.8% for the six month period.
• Gross profit decreased by 1.6% for the quarter and 3.6% for the six month period.
• Gross profit margin decreased to 55.5% for the quarter.
• The company experienced shortages of certain products, particularly eye care products, due to third-party manufacturing issues.

Risks

• The company faces economic uncertainty due to global supply chain constraints, changes in interest rates, inflation, and geopolitical events.
• There are ongoing supply chain issues, including shortages, delays, and price increases from suppliers.
• The company is dependent on third-party manufacturers, and some are having difficulty meeting demand.
• A significant portion of revenue is concentrated with a few key customers and brands.
• The company is exposed to interest rate risk due to variable rate debt.
• The company is exposed to foreign currency exchange rate risk.

Future Outlook

The company expects economic conditions to remain volatile and uncertain, potentially impacting prices, supply, and demand. They anticipate continued shifts in purchasing patterns, including increased online sales. The company believes that cash generated from operations and existing credit facilities will be adequate to finance working capital and capital expenditures for the next twelve months, excluding acquisitions.

Industry Context

The company operates in the competitive OTC healthcare market, facing challenges from both branded and store brand products. The shift to online shopping and supply chain disruptions are impacting the entire industry. The company's focus on brand development and acquisitions is a common strategy in this sector.

Comparison to Industry Standards

• Prestige's revenue decline of 0.9% for the quarter is slightly below the average growth seen in the consumer healthcare sector, which has been experiencing moderate growth.
• The company's gross profit margin of 55.5% is within the typical range for OTC healthcare companies, but there is room for improvement.
• Compared to companies like Perrigo and Haleon, Prestige's revenue is lower, but its profitability is comparable.
• The company's reliance on third-party manufacturers is a common practice in the industry, but the supply chain issues highlight a potential vulnerability.
• The company's debt levels are significant, which is typical for companies that have grown through acquisitions, but it is important to monitor the leverage ratio.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline and supply chain issues.
• Employees may be affected by potential operational changes due to supply chain disruptions.
• Customers may experience product shortages or delays.
• Suppliers may face increased pressure due to supply chain challenges.
• Creditors may be monitoring the company's debt levels and financial performance.

Next Steps

• The company will continue to monitor and manage supply chain issues.
• The company will continue to focus on brand development and acquisitions.
• The company will continue to work with GEODIS to improve logistics services.
• The company will continue to monitor and manage its debt levels.

Key Dates

Keywords

OTC Healthcare, Consumer Healthcare, Financial Results, Revenue, Net Income, Gross Profit, Supply Chain, Manufacturing, Share Repurchase, Debt, Logistics, International Sales, North American Sales